Overview

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Status:
Recruiting

Trial end date:
2024-11-18

Target enrollment:

Participant gender:

Summary

This study has dose escalation (Part A, B, C) and dose expansion (Cohorts A-L) parts. Dose escalation is to evaluate the safety, tolerability, and preliminary efficacy of MK-4830 monotherapy administration (Parts A and B) and in combination with pembrolizumab (Part C). Dose expansion is to evaluate the objective response rate (ORR) of MK-4830 in combination with pembrolizumab and evaluate the safety, tolerability and ORR of MK-4830 administered in combination with pembrolizumab and chemotherapy. There is no formal hypothesis testing in this study.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Lenvatinib
Paclitaxel
Pembrolizumab
Pemetrexed